The use of Ozempic® and Similar GLP-1 Agonists Significantly Decrease the Risk of Developing Breast Cancer in Women
1★★ Corresponding author
- 1School of Environment and Science, Nathan Campus, Griffith University, 170 Kessels Rd, Nathan, Brisbane, Queensland, AUSTRALIA.
CORRESPONDENCE
Ian Edwin Cock
School of Environment and Science, Nathan Campus, Griffith University, 170 Kessels Rd, Nathan, Brisbane, Queensland, AUSTRALIA.
Volume 16, Issue 3 (2026) · pp. 157–158 · DOI: 10.5530/pc.2026.3.18
ABSTRACT
Glucagon-like peptide-1 receptor agonists (GLP-1) are well known for their effective treatment of Diabetes mellitus (DM), their positive effects on renal and cardiovascular function, as well as for promoting weight loss.1 A recent study reported that they also significantly reduce the incidence of breast cancer in women.2 That study examined the medical records of nearly 220,000 women aged 45 to 80 years old who underwent breast imaging and analysed the rates of breast cancer detection. Interestingly, a significantly lower incidence of breast cancer was evident in women who used GLP-1 agonists compared to women not exposed to this treatment. The findings were independent of age, race and ethnicity, body mass index (BMI) and medical history of DM. Whilst this study is encouraging, directed clinical trials and determination of the protective mechanism are required to fully evaluate the potential of GLP-1 agonists as breast cancer preventative agents.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Cock, I. E. (2026). The use of Ozempic® and Similar GLP-1 Agonists Significantly Decrease the Risk of Developing Breast Cancer in Women. Pharmacognosy Communications, 16(3), 157–158. https://doi.org/10.5530/pc.2026.3.18
